News Digging > News > Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial
Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial
Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial,Merck & Co. Inc. said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of...

Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial

Merck & Co. Inc. said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of…